Tonghua Dongbao Pharmaceutical Co Ltd

SHG:600867 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.41 Billion
CN¥17.67 Billion CNY
Market Cap Rank
#6357 Global
#960 in China
Share Price
CN¥9.02
Change (1 day)
-1.42%
52-Week Range
CN¥7.06 - CN¥9.27
All Time High
CN¥23.57
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more

Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Net Assets

Latest net assets as of September 2025: CN¥7.14 Billion CNY

Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) has net assets worth CN¥7.14 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.15 Billion) and total liabilities (CN¥1.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥7.14 Billion
% of Total Assets 87.54%
Annual Growth Rate 11.52%
5-Year Change 15.13%
10-Year Change 158.18%
Growth Volatility 22.83

Tonghua Dongbao Pharmaceutical Co Ltd - Net Assets Trend (1994–2024)

This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Tonghua Dongbao Pharmaceutical Co Ltd (1994–2024)

The table below shows the annual net assets of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2024.

Year Net Assets Change
2024-12-31 CN¥6.40 Billion -11.31%
2023-12-31 CN¥7.22 Billion +10.18%
2022-12-31 CN¥6.55 Billion +5.29%
2021-12-31 CN¥6.22 Billion +11.89%
2020-12-31 CN¥5.56 Billion +10.99%
2019-12-31 CN¥5.01 Billion +5.80%
2018-12-31 CN¥4.73 Billion +4.34%
2017-12-31 CN¥4.54 Billion +15.01%
2016-12-31 CN¥3.95 Billion +59.15%
2015-12-31 CN¥2.48 Billion +14.74%
2014-12-31 CN¥2.16 Billion +7.16%
2013-12-31 CN¥2.02 Billion +1.26%
2012-12-31 CN¥1.99 Billion -4.18%
2011-12-31 CN¥2.08 Billion +19.93%
2010-12-31 CN¥1.73 Billion +6.51%
2009-12-31 CN¥1.63 Billion +13.47%
2008-12-31 CN¥1.43 Billion -6.54%
2007-12-31 CN¥1.53 Billion +20.22%
2006-12-31 CN¥1.28 Billion -4.83%
2005-12-31 CN¥1.34 Billion +1.10%
2004-12-31 CN¥1.33 Billion -5.36%
2003-12-31 CN¥1.40 Billion +2.80%
2002-12-31 CN¥1.36 Billion -1.13%
2001-12-31 CN¥1.38 Billion -3.26%
2000-12-31 CN¥1.43 Billion +1.45%
1999-12-31 CN¥1.40 Billion +51.21%
1998-12-31 CN¥928.90 Million +14.63%
1997-12-31 CN¥810.32 Million +82.36%
1996-12-31 CN¥444.36 Million +75.22%
1995-12-31 CN¥253.60 Million +4.37%
1994-12-31 CN¥242.98 Million --

Equity Component Analysis

This analysis shows how different components contribute to Tonghua Dongbao Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 11714.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.16 Billion 49.49%
Common Stock CN¥1.98 Billion 31.04%
Other Comprehensive Income CN¥1.12 Billion 17.58%
Other Components CN¥120.29 Million 1.88%
Total Equity CN¥6.38 Billion 100.00%

Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Tonghua Dongbao Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Empresa Distribuidora y Comercializadora Norte Sociedad Anónima
F:PWD1
 		$1.28 Billion
ABC-MART
F:5B8
 		$1.28 Billion
Ardelyx Inc
NASDAQ:ARDX
 		$1.29 Billion
OXFORD INSTR. PLC LS-05
F:OX3
 		$1.29 Billion
Linamar Corporation
PINK:LIMAF
 		$1.28 Billion
Kitron ASA
OL:KIT
 		$1.28 Billion
Alliance Global Group Inc
PINK:ALGGY
 		$1.28 Billion
Beijing Sojo Electric Co Ltd
SHE:300444
 		$1.28 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tonghua Dongbao Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,211,198,787 to 6,383,540,358, a change of -827,658,429 (-11.5%).
  • Net loss of 42,723,161 reduced equity.
  • Dividend payments of 495,433,518 reduced retained earnings.
  • Other comprehensive income increased equity by 1,116,976,642.
  • Other factors decreased equity by 1,406,478,392.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-42.72 Million -0.67%
Dividends Paid CN¥495.43 Million -7.76%
Other Comprehensive Income CN¥1.12 Billion +17.5%
Other Changes CN¥-1.41 Billion -22.03%
Total Change CN¥- -11.48%

Book Value vs Market Value Analysis

This analysis compares Tonghua Dongbao Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.02x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 74.60x to 3.02x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.12 CN¥9.02 x
1995-12-31 CN¥0.13 CN¥9.02 x
1996-12-31 CN¥0.22 CN¥9.02 x
1997-12-31 CN¥0.44 CN¥9.02 x
1998-12-31 CN¥0.50 CN¥9.02 x
1999-12-31 CN¥0.75 CN¥9.02 x
2000-12-31 CN¥0.78 CN¥9.02 x
2001-12-31 CN¥0.75 CN¥9.02 x
2002-12-31 CN¥0.73 CN¥9.02 x
2003-12-31 CN¥0.75 CN¥9.02 x
2004-12-31 CN¥0.70 CN¥9.02 x
2005-12-31 CN¥0.71 CN¥9.02 x
2006-12-31 CN¥0.62 CN¥9.02 x
2007-12-31 CN¥0.70 CN¥9.02 x
2008-12-31 CN¥0.87 CN¥9.02 x
2009-12-31 CN¥0.89 CN¥9.02 x
2010-12-31 CN¥1.08 CN¥9.02 x
2011-12-31 CN¥0.97 CN¥9.02 x
2012-12-31 CN¥1.10 CN¥9.02 x
2013-12-31 CN¥1.14 CN¥9.02 x
2014-12-31 CN¥1.19 CN¥9.02 x
2015-12-31 CN¥1.49 CN¥9.02 x
2016-12-31 CN¥2.36 CN¥9.02 x
2017-12-31 CN¥2.65 CN¥9.02 x
2018-12-31 CN¥2.31 CN¥9.02 x
2019-12-31 CN¥2.47 CN¥9.02 x
2020-12-31 CN¥2.75 CN¥9.02 x
2021-12-31 CN¥3.04 CN¥9.02 x
2022-12-31 CN¥3.32 CN¥9.02 x
2023-12-31 CN¥3.64 CN¥9.02 x
2024-12-31 CN¥2.99 CN¥9.02 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tonghua Dongbao Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -0.67%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -2.13%
  • • Asset Turnover: 0.27x
  • • Equity Multiplier: 1.16x
  • Recent ROE (-0.67%) is below the historical average (10.53%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 19.92% 36.68% 0.50x 1.10x CN¥24.10 Million
1995 26.84% 32.08% 0.65x 1.29x CN¥42.72 Million
1996 18.35% 36.44% 0.45x 1.12x CN¥37.09 Million
1997 11.18% 44.13% 0.23x 1.08x CN¥9.60 Million
1998 9.70% 40.01% 0.19x 1.31x CN¥-2.70 Million
1999 4.93% 30.77% 0.15x 1.09x CN¥-69.56 Million
2000 0.25% 1.78% 0.14x 1.04x CN¥-138.25 Million
2001 0.31% 2.03% 0.14x 1.06x CN¥-133.02 Million
2002 3.03% 14.27% 0.18x 1.19x CN¥-92.18 Million
2003 2.66% 12.10% 0.17x 1.32x CN¥-99.68 Million
2004 -6.11% -25.42% 0.17x 1.41x CN¥-206.24 Million
2005 1.25% 4.91% 0.17x 1.45x CN¥-113.42 Million
2006 0.98% 3.00% 0.20x 1.60x CN¥-111.24 Million
2007 5.19% 16.48% 0.21x 1.52x CN¥-71.77 Million
2008 3.36% 8.50% 0.25x 1.56x CN¥-92.56 Million
2009 4.63% 12.85% 0.25x 1.41x CN¥-85.57 Million
2010 10.49% 27.97% 0.29x 1.29x CN¥8.40 Million
2011 17.79% 46.68% 0.33x 1.16x CN¥159.38 Million
2012 3.20% 6.32% 0.42x 1.21x CN¥-133.46 Million
2013 9.24% 15.27% 0.45x 1.35x CN¥-15.20 Million
2014 13.09% 19.28% 0.49x 1.38x CN¥66.01 Million
2015 20.04% 29.53% 0.44x 1.54x CN¥247.03 Million
2016 16.27% 31.41% 0.44x 1.19x CN¥247.00 Million
2017 18.48% 32.87% 0.54x 1.05x CN¥383.77 Million
2018 17.75% 31.14% 0.49x 1.16x CN¥366.18 Million
2019 16.22% 29.21% 0.52x 1.07x CN¥311.17 Million
2020 16.74% 32.15% 0.50x 1.04x CN¥374.52 Million
2021 21.05% 40.03% 0.50x 1.05x CN¥686.77 Million
2022 24.17% 56.93% 0.41x 1.03x CN¥927.47 Million
2023 16.19% 37.97% 0.40x 1.08x CN¥446.72 Million
2024 -0.67% -2.13% 0.27x 1.16x CN¥-681.08 Million

Industry Comparison

This section compares Tonghua Dongbao Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tonghua Dongbao Pharmaceutical Co Ltd (600867) CN¥7.14 Billion 19.92% 0.14x $1.28 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million